Literature DB >> 17562183

Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics.

Benedikt Fischer1, Eugenia Oviedo-Joekes, Peter Blanken, Christian Haasen, Jürgen Rehm, Martin T Schechter, John Strang, Wim van den Brink.   

Abstract

Since the initial Swiss heroin-assisted treatment (HAT) study conducted in the mid-1990s, several other jurisdictions in Europe and North America have implemented HAT trials. All of these studies embrace the same goal-investigating the utility of medical heroin prescribing for problematic opioid users-yet are distinct in various key details. This paper briefly reviews (initiated or completed) studies and their main parameters, including primary research objectives, design, target populations, outcome measures, current status and-where available-key results. We conclude this overview with some final observations on a decade of intensive HAT research in the jurisdictions examined, including the suggestion that there is a mounting onus on the realm of politics to translate the-largely positive-data from completed HAT science into corresponding policy and programming in order to expand effective treatment options for the high-risk population of illicit opioid users.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562183      PMCID: PMC2219559          DOI: 10.1007/s11524-007-9198-y

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  28 in total

1.  [Economic evaluation of the Swiss project on medically prescribed heroin substitution treatment].

Authors:  A Frei
Journal:  Psychiatr Prax       Date:  2001-07

2.  NAOMI--her time has come. North American Opiate Medication Initiative.

Authors:  Martin T Schechter
Journal:  J Urban Health       Date:  2002-06       Impact factor: 3.671

3.  Criminal outcomes and costs of treatment services for injecting and non-injecting heroin users: evidence from a national prospective cohort survey.

Authors:  Andrew Healey; Martin Knapp; John Marsden; Michael Gossop; Duncan Stewart
Journal:  J Health Serv Res Policy       Date:  2003-07

4.  What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing?

Authors:  Gabriele Bammer; Wim van den Brink; Patrick Gschwend; Vincent Hendriks; Jürgen Rehm
Journal:  Drug Alcohol Rev       Date:  2003-09

5.  Why we object to NAOMI. Heroin maintenance in Canada.

Authors:  Meldon Kahan; Anita Srivastava; Kay Shen
Journal:  Can Fam Physician       Date:  2006-06       Impact factor: 3.275

Review 6.  Heroin maintenance treatment for chronic heroin-dependent individuals: a Cochrane systematic review of effectiveness.

Authors:  Marica Ferri; Marina Davoli; Carlo A Perucci
Journal:  J Subst Abuse Treat       Date:  2006-01

7.  Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials.

Authors:  Marcel G W Dijkgraaf; Bart P van der Zanden; Corianne A J M de Borgie; Peter Blanken; Jan M van Ree; Wim van den Brink
Journal:  BMJ       Date:  2005-06-04

8.  A 33-year follow-up of narcotics addicts.

Authors:  Y I Hser; V Hoffman; C E Grella; M D Anglin
Journal:  Arch Gen Psychiatry       Date:  2001-05

9.  Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials.

Authors:  Wim van den Brink; Vincent M Hendriks; Peter Blanken; Maarten W J Koeter; Barbara J van Zwieten; Jan M van Ree
Journal:  BMJ       Date:  2003-08-09

10.  Methodology for the Randomised Injecting Opioid Treatment Trial (RIOTT): evaluating injectable methadone and injectable heroin treatment versus optimised oral methadone treatment in the UK.

Authors:  Nicholas Lintzeris; John Strang; Nicola Metrebian; Sarah Byford; Christopher Hallam; Sally Lee; Deborah Zador
Journal:  Harm Reduct J       Date:  2006-09-27
View more
  26 in total

1.  Should heroin be prescribed to heroin misusers? Yes.

Authors:  Jürgen Rehm; Benedikt Fischer
Journal:  BMJ       Date:  2008-01-12

2.  Substance misuse: More than a quick fix.

Authors:  Tony Sheldon
Journal:  BMJ       Date:  2008-01-12

3.  Post-war prevention: Emerging frameworks to prevent drug use after the War on Drugs.

Authors:  Dan Werb
Journal:  Int J Drug Policy       Date:  2017-07-19

4.  Stigma and substance use disorders: A clinical, research, and advocacy agenda.

Authors:  Valerie A Earnshaw
Journal:  Am Psychol       Date:  2020-12

5.  Negotiating the Relationship Between Addiction, Ethics, and Brain Science.

Authors:  Daniel Z Buchman; Wayne Skinner; Judy Illes
Journal:  AJOB Neurosci       Date:  2010-01

6.  Motivations to initiate injectable hydromorphone and diacetylmorphine treatment: A qualitative study of patient experiences in Vancouver, Canada.

Authors:  Samara Mayer; Al Fowler; Isabella Brohman; Nadia Fairbairn; Jade Boyd; Thomas Kerr; Ryan McNeil
Journal:  Int J Drug Policy       Date:  2020-09-16

7.  Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets.

Authors:  Ludwig Perger; Katharina M Rentsch; Gerd A Kullak-Ublick; Davide Verotta; Karin Fattinger
Journal:  Eur J Pharm Sci       Date:  2008-11-25       Impact factor: 4.384

Review 8.  Prescription of heroin for the management of heroin dependence: current status.

Authors:  Nicholas Lintzeris
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure.

Authors:  Ulrike Halbsguth; Katharina M Rentsch; Dominique Eich-Höchli; Isabel Diterich; Karin Fattinger
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

10.  Efficacy of prescribed injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders and non-responders according to a multi domain outcome index.

Authors:  Emilio Perea-Milla; Luis Carlos Silva Ayçaguer; Joan Carles March Cerdà; Francisco González Saiz; Francisco Rivas-Ruiz; Alina Danet; Manuel Romero Vallecillo; Eugenia Oviedo-Joekes
Journal:  Trials       Date:  2009-08-14       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.